Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...

The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...

Merck and Daiichi Sankyo acknowledged a "voluntary pause" in the phase III program for the investigational antibody-drug conjugate ifinatamab deruxtecan following a higher-than-expected number of ...

Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.